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OBJECTIVE—Wepreviouslyfoundthatmicroalbuminuria(MA)ispresentin14%ofpatients
withlong-standingcysticﬁbrosis–relateddiabetes(CFRD).However,othershavereportedmuch
higherratesof MAinCF patientswith and withoutdiabetes(32–67%),suggesting thistestisnot
sufﬁciently speciﬁc for diabetic nephropathy screening in CF. We investigated transient (TMA)
and persistent (PMA) microalbuminuria in CF patients to resolve these contradictory ﬁndings.
RESEARCH DESIGN AND METHODS—We reviewed 1,449 outpatient urinary albu-
minmeasurementsfrom 467patientsaged $10years, which were collectedover a decade.TMA
was deﬁned as a single episode of MA that subsequently was resolved. PMA was deﬁned as two
consecutive or two out of three consecutive measurements in the MA range.
RESULTS—The prevalence of TMA that subsequently was resolved in CF patients was similar
to the general population. It was found in 7.6% of patients, including 5% of youth (aged 10–17
years) and 9% of adults. PMA was found in 6.1% of the overall CF population, including 2% of
youth and 8% of adults. The odds of PMA were increased sevenfold in patients with CFRD (95%
CI 2.5–20, P = 0.0002) and 48-fold in patients with both CFRD and organ transplant (95% CI
13–177,P,0.0001).The ﬁve patientswith PMA intheabsenceofCFRDor transplant included
two youths with presumed benign orthostatic MA and three adults with hypertension.
CONCLUSIONS—The spot urine albumin-to-creatinine ratio is speciﬁc enough to be a valid
screening test for diabetic kidney disease in CFRD.
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A
nnual urine albumin screening is
recommended for people with type
1a n dt y p e2d i a b e t e st od e t e c te a r l y
evidence of diabetic kidney disease (1).
Elevated urine albumin is also found in
patients with cystic ﬁbrosis–related dia-
betes (CFRD) (2–6). In a study of 192
CFRDpatients,wepreviouslyreportedthat
microalbuminuria (MA) was present in
14% of those with long-standing (.10
years) CFRD and, as inthe general diabetic
population, was associated with worse gly-
cemic control(2).Two other groups,how-
ever, have questioned the validity of this
association because they found MA to be
far more common in CF, even in patients
without diabetes (7,8). Dobson et al. (7)
reported that MA was present in 67% of
single urine samples from six CF patients
with diabetes and in 32% of 34 samples
fromCFpatientswithoutdiabetes.Another
European study (8) found a 58% preva-
lence of MA in 112 children with CF,
none of whom had diabetes. Thus, it was
suggested that urine albumin excretion
(UAE) may not be speciﬁc enough to be
used as a screening measure for the detec-
tion of diabetic kidney disease in CFRD.
The current study attempts to resolve
these contradictory ﬁndings by determin-
ing the prevalence of both transient and
persistent MA in CF patients with and
without diabetes during routine screening
at a large pediatric and adult CF center.
RESEARCH DESIGN AND
METHODS—CF patients at the Uni-
versity of Minnesota (UM) CF Center are
routinely seen at quarterly intervals, and
their clinical and laboratory data are re-
corded in a database. Annual oral glucose
tolerance test screening starts at age 6 years
for patients not already on insulin treat-
ment. Additional routine lung function,
anthropometric measurement, and blood
andurine laboratory studies are performed
annuallyatatimewhenpatientsareintheir
stable baseline state of health. Annual spot
urine testing for quantitative albumin
determination was introduced as partof
routine annual studies starting in 2001,
and performance of this measurement
became increasingly common over the
subsequent decade.
Pediatric patients were deﬁned as
,18 years of age. Hypertension was de-
ﬁned as systolic blood pressure .140
mmHg or diastolic blood pressure .90
mmHgforCFadults,bloodpressurecon-
sistently above the 95th percentile for age
and sex for children, or antihypertensive
medication treatment during the study pe-
riod. Transplant status was recorded.
Review of this prospectively collected
data was performed to determine the prev-
alence of MA during the period between
January 2001 and February 2010. All pa-
tients and their parents gave informed
consent/assent, permitting their records to
bereviewedforresearchpurposes.Thiswas
approved by the UM Institutional Review
Board.
Urine albumin assessment
Urine samples from inpatient hospitaliza-
tions and from patients ,10 years of age
were excluded. Urine albumin and creati-
nine were measured in the UM Fairview
laboratory using nephelometry. MA was
deﬁned as an albumin-to-creatinine ratio
(ACR) 30–299 mg/g. Macroalbuminuria
was deﬁned as an ACR $300 mg/g. MA
was considered transient or persistent:
transientmicroalbuminuria(TMA)wasde-
ﬁned as a single episode that subsequently
resolved, while persistent microalbumin-
uria (PMA) was deﬁned as an ACR in the
MA range in at least two consecutive or
two of three consecutive measurements.
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ORIGINAL ARTICLEtwo patients with MA who each had only
one urinary albumin measurement.
Data analysis
Observationswerecollectedoveraperiod
of 10 years, and many were repeated mea-
surements from the same patient. For the
analysis,weusedtheﬁrsturinecollection
from patients with all normal ACRs, the
ﬁrst urinecollection withACR $30 mg/g
for patients with TMA, and the second
(conﬁrmatory) urine collection with ACR
$30mg/gforpatientswithPMA.Thestudy
sample was divided into three ACR groups:
those with all normal ACRs, those with
TMA, and those who met PMA criteria.
There were three deceased patients
who underwent lung transplants and for
whom only pretransplant urine albumin
data were analyzed. They are therefore re-
ported in the no-transplant group. They
included one male subject who died the
day of the transplant and two others who
developedpersistentrenalfailureunrelated
to diabetes as a complication of a difﬁcult
postoperative course.
Cumulative prevalence of MA was es-
timatedbydividingthenumberofsubjects
in each ACR group by the total number of
patients.Continuous variables were com-
pared among groups by ANOVA, and
categoricaloutcomeswerecomparedusing
x
2 tests. P values , 0.05 were considered
statistically signiﬁcant. Separate analyses
were performed by CFRD and transplant
status. Odds ratios were calculated using a
generalized logit model for probabilities of
the three ACR categories (9). All computa-
tionswereperformedusingSASversion9.2.
RESULTS
Cumulative prevalence of MA
During the study period, 200122010,
there were 1,449 ACR measurements re-
corded on 467 patients, comprising 75%
ofallpatientsaged $10yearsseenduring
this period. One-third of the study pa-
tients were youth aged 10–17 years at
the time of the ﬁrst urine collection, and
there were equal numbers of males and
females. Seventy-six percent of the study
cohort had at least two or more recorded
urine collections.
The cumulative prevalence of TMA
that subsequently resolved was 7.6% in all
patients,5%inyouth,and9%inadults.The
cumulative prevalence of PMA was 6.1%
overall, 2% in youth, and 8% in adults.
Prevalence rates varied greatly depending
on CFRD and transplant status. Patients
withCFRDwithnohistoryoflungorliver
transplant (n = 149) had no increase in
oddsofTMA(95%CI0.5–2.4),but seven-
fold greater odds of PMA (95% CI 2.5–20,
P=0.0002).Patientswithahistoryoforgan
transplantation (n = 20, 19 of whom also
had CFRD and 1 with impaired glucose
tolerance) had nearly fourfold greater
odds of TMA (95% CI 1.0–16, P =0 . 0 4 4 )
and a 48-fold increase in the odds of PMA
(95% CI 13–177, P , 0.0001). Only ﬁve
patients with PMA (17%) did not have ei-
ther CFRD or a history of transplant. Two
of these were adolescents with intermittent
MA, which was presumed to be benign
orthostatic microalbuminuria. The other
threewereadultpatientswithhypertension,
a known risk factor for MA.
Prevalence of macroalbuminuria
and kidney failure
T h e r ew e r e1 4p a t i e n t s( 3 % )w i t ha tl e a s t
one urine collection in the macroalbumi-
nuric range. Only two of these patients did
not have CFRD and/or a history of trans-
plant. Both patients were youth who had
macroalbuminuria on only one occasion
withsubsequentimprovement(oneintothe
normal range and one into the MA range).
A 48-year-old man with an 18-year
history of poorly controlled diabetes de-
veloped diabetic nephropathy and received
a kidney transplant. He is the third CF
patient ever to require dialysis for diabetic
nephropathy at UM, and the ﬁrst to
receive a renal transplant. Of 20 patients
followed during the study period who
had a history of lung or liver transplant, 8
developed chronic kidney disease, which
was felt to be secondary to nephrotoxic
antirejection medications rather than to
diabetes. Two of these patients received
kidney transplants between 2 and 5 years
after their initial organ transplant, and
another is currently on the transplant list.
Patient characteristics
Clinical characteristics were compared
among patients with normal ACR, TMA,
and PMA (Table 1). For patients who did
nothaveCFRDoranorgantransplant(n=
298), apart from a higher prevalence of
antihypertensive medications in TMA,
there were no statistically signiﬁcant clin-
ical differences between ACR categories.
Among CFRD patients with (n = 20) or
without (n = 149) transplant, those with
TMA and PMA were older and tended to
have higher mean blood pressures, higher
serum creatinine values, and worse lung
function compared with those in the nor-
mal ACR group, although these differences
did not always reach statistical signiﬁcance.
CONCLUSIONS—In the U.S. adult
general population, the prevalence of MA
on random screening has been reported to
be 6–7% in patients without known risk
factors such as diabetes or hypertension
(10–12). In healthy adolescents aged 11–
17 years in the general population, the
prevalence of MA was 8% on single urine
samplesbutdecreasedto0.8%uponrepeat
testing(13).Similarly,routineclinicscreen-
ing of youth and adults with CF over a
period of 10 years showed TMA that sub-
sequently normalized in 7.6% of patients.
PMA was found in 6.1% of CF patients,
primarily in those with CFRD and espe-
c i a l l yi nt h o s ew i t hb o t hC F R Da n dah i s -
tory of transplant. Thus, contrary to some
previousreports(7,8),excessiveUAEisnot
unusually common in CF patients.
Inthegeneralpopulation,severalnon-
renal and renal factors can elevate UAE.
Nonrenal factors that transiently increase
urine albumin include fever, illness, day-
time collection (benign orthostasis), and
heavy exercise. Renal disease risk factors
to which CF patients are prone include
diabetic microvascular disease, nephroli-
thiasis,andexposuretonephrotoxicagents
such as aminoglycoside antibiotics or post-
transplant antirejection drugs (14). In the
current report, PMA was found in about
halfofpatientsfollowinglungorlivertrans-
plant. The etiology in these cases is likely
multifactorial, including complications of
surgery, nephrotoxic antirejection medica-
tions, diabetes, and hypertension. Macroal-
buminuriawasrare,andtherewasonlyone
case of diabetic nephropathy requiring
kidney transplant.
Other studies that described much
higherratesofMAinCFpatients,including
patients without diabetes, had much
smaller sample sizes and limited or no
follow-up data (7,8). Dobsonetal. (7) sug-
gestedthattheelevatedACRwasbecauseof
the combination of both increased urinary
albumin due to chronic infection and re-
duced urine creatinine related to low mus-
cle mass. This may be less relevant in the
current report because ACR was evaluated
during routine annual studies, which are
always done during a period of stable
health, and because CF patients at UM
are generally well nourished.
The current study has some limita-
tions. Urinary measurements were obtained
at clinic visits, which might lead to higher
ACRvaluescomparedwithmorningvoidor
overnight urine collections. Thus, we may
have overestimated the prevalence of MA
by including patients with a postural com-
ponent to their increased ACR values. The
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Lind-Ayres and Associatesstudy might have been enhanced by a pro-
spective collection of data on antibiotic use,
number and timing of pulmonary exacer-
bations, and formal measurements of glo-
merular ﬁltration rate.
In summary, we evaluated a large,
well-described CF outpatient clinic pop-
ulation over a period of about 10 years.
TMA was no more common than in the
generalpopulation.PMAwasfoundinonly
6.1%ofpatients,themajorityofwhomhad
diabetes. Thus, as in the general diabetic
population, the spot urine ACR is speciﬁc
enough to be a valid screening measure for
theassessmentofdiabetickidneydiseasein
patients with CFRD.
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Table 1—Demographic and clinical characteristics of patients with normoalbuminuria
(normal ACR), TMA, and PMA, stratiﬁed by CFRD-transplant status
Normal ACR TMA PMA P value
Neither CFRD nor transplant (n) 271 22 5 —
Female (%) 44 59 80 0.13
Adult (age .17 years) (%) 57 64 60 0.82
Age (years) 23 6 12 7 6 32 4 6 5 0.29
ACR (mg/g) 4.5 (4–5) 65 (49–85) 121 (692210) —
Serum Cr (mg/dL) 0.76 6 0.01 0.84 6 0.05 0.66 6 0.10 0.18
SBP (mmHg) 108 6 11 1 4 6 5 115 6 13 0.50
DBP (mmHg) 65 6 16 3 6 37 4 6 6 0.29
Hypertensive medication (%) 0.4 9 0 0.0004
FEV1 (%) 79 6 26 8 6 66 4 6 12 0.11
CFRD only (n) 122 11 16 —
Female (%) 46 45 63 0.39
Adult (age .17 years) (%) 83 100 94 0.22
Age (years) 27 6 1
a 34 6 3
b 35 6 2
b 0.002
ACR (mg/g) 5 (426) 71 (432117) 260 (1702394) —
Serum Cr (mg/dL) 0.8 6 0.04
a 1.2 6 0.1
b 1.5 6 0.2
b ,0.0001
SBP (mmHg) 112 6 2
a 127 6 6
b 127 6 7
b 0.01
DBP (mmHg) 66 6 1
a 74 6 4
ab 76 6 4
b 0.02
Hypertensive medication (%) 4 9 19 0.06
FEV1 (%) 65 6 3
a 51 6 8
ab 45 6 7
b 0.01
Transplant (n)* 9 3 8 —
Female (%) 67 33 63 0.68
Adult (age .17 years) (%) 89 100 100 0.48
Age (years) 36 6 43 6 6 63 5 6 4 0.99
ACR (mg/g) 8 (4215) 35 (102125) 108 (502235) —
Serum Cr (mg/dL) 1.3 6 0.3 1.9 6 0.7 2.0 6 0.4 0.43
SBP (mmHg) 126 6 61 4 1 6 12 134 6 6 0.48
DBP (mmHg) 75 6 48 1 6 87 9 6 4 0.73
Hypertensive medication (%) 83 67 100 0.26
FEV1 (%) 79 6 4 — 82 6 6 0.74
Values are mean 6 SE or percentage; ACR is reported as a geometric mean (95% CI). Cr, creatinine; DBP,
diastolic blood pressure; FEV1, percentpredicted expiratory volume in 1 s; SBP, systolic blood pressure. a,b,
means with no shared letters were signiﬁcantly different (P , 0.05); means with shared letters were not
signiﬁcantly different. *All patients in this stratum also had CFRD except for one patient with impaired
glucose tolerance.
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